# Blue Note Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blue-note-therapeutics

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.bluenotetherapeutics.com
- Total disclosed funding: $15M
- Latest round: Series A (Aug 24, 2021)
- Investors on record: 5

## About

Based in the US, Blue Note Therapeutics specializes in developing evidence-based therapeutics, aimed at enhancing treatment options for cancer patients through innovative solutions.Blue Note Therapeutics, Inc. focuses on creating evidence-based therapeutics for cancer patients. The company is headquartered in San Francisco, US. Geoffrey Eich serves as the CEO. In August 2021, the company raised USD 2.47 mn in SERIES A funding, led by JAZZ Venture Partners and Summer VC, with participation from Alumni Ventures Group and Memorial Sloan-Kettering Cancer Center Pension Plan. This funding is part of a larger USD 31.45 mn SERIES A round and is intended to support the development of their therapeutic offerings.Blue Note Therapeutics is engaged in the sale and leasing of premium domain names, notably the domain name "bluenotetherapeutics.com." The company provides a seamless transaction process, allowing clients to purchase or lease domain names essential for their online presence, particularly in the healthcare and wellness sectors. Their service offerings include immediate purchase options and leasing arrangements tailored to the needs of various businesses and individuals across multiple regions.Blue Note Therapeutics generates revenue primarily from the sale and leasing of its domain names. Clients can purchase the domain outright for USD 4,911 or select a Lease to Own plan at USD 226 per month. This pricing model accommodates diverse client needs, including both direct consumers and businesses seeking a robust online identity. The company also provides secure payment options and transaction support, enhancing the overall reliability of its services.In August 2021, Blue Note Therapeutics, Inc. secured USD 2.47 mn in SERIES A funding aimed at developing innovative therapeutics for cancer patients. The funds will be utilized to expand their offerings and potentially enter new markets. The company plans to enhance its product line with upcoming evidence-based therapeutics, although specific release dates for new products have not been disclosed. With the recent funding, Blue Note Therapeutics is positioned to broaden its impact within the oncology sector, aligning with their goal of serving a growing patient population.

## Funding rounds

- Series A, Aug 24, 2021, $2.5M — Memorial Sloan-Kettering Cancer Center Pension Plan, Alumni Ventures Group, JAZZ Venture Partners, Summer VC
- Series A, Feb 1, 2021, $13M — JAZZ Venture Partners, Summer Capital

## Investors

- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A
- Summer Capital — Series A
- Memorial Sloan-Kettering Cancer Center Pension Plan — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Summer VC — Series A